Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Stephen Stark

Interventional Cardiology Inverness, FL Medical Doctor

NPI 1912981119 CMS profile 267871

308 W Highland Blvd, Inverness, FL 34452

Open in the dashboard

General payments

$2,033

76 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Stephen Stark of Inverness, FL is reported in the CMS Open Payments database as having received $2,033 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 20th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $17 1
2023 General $69 2
2022 General $348 19
2021 General $509 17
2020 General $494 19
2019 General $596 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Stark
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Stephen Stark were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Stephen Stark Interventional Cardiology median Middle half National median
2019 $596 $1,097 $329–$3,048 $163
2020 $494 $473 $161–$1,480 $114
2021 $509 $677 $233–$1,827 $132
2022 $348 $978 $333–$2,724 $149
2023 $69 $1,136 $382–$2,986 $160
2024 $17 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Abbott Laboratories $453 20 payments
  2. W. L. Gore & Associates, Inc. $290 2 payments
  3. Amgen Inc. $228 12 payments
  4. Medtronic, Inc. $179 8 payments
  5. Venclose Inc. $125 1 payment
  6. Bard Peripheral Vascular, Inc. $119 1 payment
  7. Biosense Webster, Inc. $105 2 payments
  8. Medtronic Vascular, Inc. $90 5 payments
  9. Boston Scientific Corporation $80 4 payments
  10. AstraZeneca Pharmaceuticals LP $74 5 payments
  11. Other $289 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,847 74 payments
  2. Travel and Lodging $148 1 payment
  3. Debt forgiveness $38 1 payment
Products named General payments · program years 2019–2024
  1. VIABAHN Endoprosthesis $290 2 payments
  2. Carto 3 $270 3 payments
  3. Repatha $228 12 payments
  4. EVRSF $125 1 payment
  5. Confirm Rx $92 4 payments
  6. SmartAblate $90 1 payment
  7. Quadra Assura CRT Defibrillator Cardiac Rhythm Management $72 3 payments
  8. Micra $69 2 payments
  9. AZURE XT DR MRI SURESCAN $69 3 payments
  10. Quadra Assura CRT Defibrillator Cardiac Arrhythmias and Heart Failure $66 3 payments
  11. Other $944 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record